POINT OF VIEW

A class of drugs known as GLP-1s have gained rapid attention as groundbreaking treatments for obesity, however their impact goes beyond just weight – and the behavior changes they induce have potential to make a massive impact on the global economy.

The drugs work by mimicking the effects of a hormone which regulates appetite, insulin secretion, and glucose metabolism, effectively reducing hunger and increasing feelings of fullness.

Originally developed as a treatment for diabetes, uptake has been staggering since the drugs were approved for weight loss, reflecting GLP-1s’ efficacy and growing acceptance. And the potential uptake goes further: an Ipsos Consumer Tracker survey in October 2024 found that more than half of all Americans (53%) are interested in taking a drug that would help reduce cravings to eat, resulting in weight loss.

With all this growth potential, other pharmaceutical companies are now developing new GLP-1 agents or similar products. Ultimately, GLP-1s’ unprecedented success to date, the promise they’ve shown in treating multiple other diseases, and the myriad conditions that could be prevented or alleviated by weight loss all point to a coming revolution in healthcare.

However, our latest report looks beyond healthcare, exploring how the changing consumption habits of this emerging population can impact sectors far beyond health and wellness. Read on to learn more about how a slimmer population is likely to immediately affect sectors like food, beverage and restaurants, as well as sectors like retail, beauty and even aviation.